Literature DB >> 20514635

[Satisfaction of the migraine patient attending neurology clinics: results of CIEN-mig project (II)].

Julio Pascual1, Margarita Sánchez del Río, María Dolores Jiménez, José Miguel Láinez-Andrés, Valentín Mateos, Rogelio Leira, Patricia Pozo-Rosich, Carlos Guzmán-Quilo.   

Abstract

INTRODUCTION: Migraine is the most common neurological consultation in our country. AIM. To analyse the satisfaction level of the patient with migraine attending our clinics. PATIENTS AND METHODS: A total of 160 neurologists asked 10 consecutive migraine patients to fill in a satisfaction questionnaire.
RESULTS: The questionnaire was answered by 1330 patients. The most important factors they considered for their neurologists were professional experience and kindness. Patients thought neurologist should improve in time to explain treatment and accessibility. Almost 90% of patients considered that treatments for migraine had improved, but almost half of them were not satisfied with the management in primary care setting. Patients were more satisfied with symptomatic treatment (69.1%) than with preventatives (50.4%). More than half had a neuroimaging study due to their headaches. Only half thought that such an study would improve their satisfaction.
CONCLUSIONS: The level of satisfaction of the migraine patient attending our clinics has improved in the last years. In patients' opinion the aspects which should be improved are the time to explain migraine and its treatment, accessibility and preventive treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20514635

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  1 in total

1.  Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention.

Authors:  Andre Leite Gonçalves; Adriana Martini Ferreira; Reinaldo Teixeira Ribeiro; Eliova Zukerman; José Cipolla-Neto; Mario Fernando Prieto Peres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-05-10       Impact factor: 10.154

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.